(1 - 24 from 37
)
Review Period for Eli Lilly's RA Therapy Baricitinib Extended by FDA
rheumatoidarthritisnews.com
“At Lilly, we are committed to improving the lives of people with life-long chronic diseases such as rheumatoid arthritis, a serious and disabling type of arthritis,” J. Anthony Ware, MD, senior vice president of product development and interim president of Eli Lilly Biomedicines, said in a press release. “We will ...
Results of Clinical and Patient-Reported Outcomes Data for...
investor.lilly.com
... Congress of Rheumatology (EULAR 2016)," said J. Anthony Ware , M.D., senior vice president, product development, Lilly Bio-Medicines.
sorted by relevance / date